Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $2.8 million.

  • Ocular Therapeutix's Interest Expenses fell 882.16% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.8 million, marking a year-over-year decrease of 1283.79%. This contributed to the annual value of $11.8 million for FY2025, which is 1283.05% down from last year.
  • Per Ocular Therapeutix's latest filing, its Interest Expenses stood at $2.8 million for Q4 2025, which was down 882.16% from $3.0 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Interest Expenses high stood at $4.2 million for Q4 2023, and its period low was $1.7 million during Q2 2021.
  • Moreover, its 5-year median value for Interest Expenses was $2.4 million (2023), whereas its average is $2.5 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Interest Expenses surged by 12912.9% in 2024, and later tumbled by 2633.92% in 2025.
  • Over the past 5 years, Ocular Therapeutix's Interest Expenses (Quarter) stood at $1.7 million in 2021, then grew by 9.94% to $1.8 million in 2022, then skyrocketed by 124.74% to $4.2 million in 2023, then dropped by 25.17% to $3.1 million in 2024, then fell by 8.82% to $2.8 million in 2025.
  • Its Interest Expenses stands at $2.8 million for Q4 2025, versus $3.0 million for Q3 2025 and $3.0 million for Q2 2025.